Disease Info Card

Hamartoma Syndrome, Multiple

Information about Hamartoma Syndrome, Multiple: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Hamartoma Syndrome, Multiple

Most recent studies have shown that Hamartoma Syndrome, Multiple shares some biological mechanisms with adenomatous-polyposis-coli, bannayan-riley-ruvalcaba-syndrome, carcinoma, ganglioneuroma, hamartoma, lhermitte-duclos-disease, macrocephaly, malignant-neoplasm-of-breast, malignant-neoplasm-of-thyroid, malignant-neoplasms, malignant-paraganglionic-neoplasm, mammary-neoplasms, neoplasms, neoplasms-multiple-primary, neoplastic-syndromes-hereditary, peutz-jeghers-syndrome, polyposis, polyps, skin-neoplasms, thyroid-neoplasm.

Among the many pathways, these few ones have gauged particular interests from scientists studying Hamartoma Syndrome, Multiple, and have been seen in publications frequently: Angiogenesis, Cell Cycle, Cell Cycle Arrest, Cell Death, Cell Differentiation, Cell Growth, Cell Migration, Cell Proliferation, Demethylation, Hyperphosphorylation, Keratinization, Localization, Methylation, Mismatch Repair, Oncogenesis, Pathogenesis, Pigmentation, Protein Phosphorylation, Regulation Of Cell Growth, Translation

Quite a number of genes have been found to play important roles in Hamartoma Syndrome, Multiple, such as AKT1, APC, BMPR1A, BRCA1, BRCA2, CS, LYPD1, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PTEN, RET, SMAD4, STK11, TEP1, TP53, TSC1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.